Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma.
Τίτλος | Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. |
Publication Type | Journal Article |
Year of Publication | 2006 |
Authors | Katodritou, E., Speletas M., Zervas K., Kapetanos D., Georgiou E., Christoforidou A., Pavlitou A., Sion M., & Christakis J. |
Journal | Lab Hematol |
Volume | 12 |
Issue | 1 |
Pagination | 47-54 |
Date Published | 2006 |
ISSN | 1080-2924 |
Λέξεις κλειδιά | Adult, Aged, Aged, 80 and over, Anemia, Hypochromic, Erythrocyte Count, Erythropoietin, Female, Humans, Male, Middle Aged, Monitoring, Physiologic, Multiple Myeloma, Recombinant Proteins |
Abstract | The purpose of this study was to evaluate the sTfR-F index and hypochromic erythrocytes (HYPO%) as potential predictors of response to recombinant human erythropoietin (r-HuEPO) of anemic patients with multiple myeloma (MM) before treatment, as well as early in the course of treatment. Twenty-six newly diagnosed anemic MM patients received r-HuEPO 30,000 IU/wk sc, for six weeks. The sTfR-F index and HYPO% were determined at baseline and at weeks 2 and 6. Patients were classified in 1 of 4 categories of a diagnostic plot, according to erythropoietic state (ES I-IV), defined by the combination of sTfR-F index and HYPO%. Sixteen of 20 patients in ES I and II before treatment responded to r-HuEPO, whereas none of the 6 patients in ES III and IV responded (P < .001). At week 2, 44% of patients who responded and 60% of the nonresponders were in functional iron deficiency (FID) and the proportion increased to 69% and 80%, respectively, by week 6. Seven of the patients who did not respond received in addition 200 mg iron sucrose IV weekly, for the next 4 weeks, and 6 of them responded. These results suggest that combination of sTfR-F index and HYPO% in a diagnostic plot can be used as a predictive model to recognize patients who will benefit from r-HuEPO and identify FID requiring iron supplementation, before treatment and early in the course of treatment, contributing thus to optimization of r-HuEPO therapy. |
DOI | 10.1532/LH96.05030 |
Alternate Journal | Lab Hematol |
PubMed ID | 16513546 |